Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.
Author(s) -
Akira Kabashima,
Koichi Kimura,
Kensakuet Sanefuji,
Soichiro Maekawa
Publication year - 2017
Publication title -
fukuoka igaku zasshi = hukuoka acta medica
Language(s) - English
DOI - 10.15017/1808303
Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe andfeasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a completeresponse (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resectionand additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multipleliver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Livermetastases could not be identified using CT after the end of the sixth course. Grade 1peripheralneuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen waschanged to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after theregimen change.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom